HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SKB BIO-B

285.400

-3.600-1.25%

Volume:811.90K

Turnover:232.78M

Market Cap:64.79B

PE:-223.03

High:294.000

Open:285.000

Low:275.000

Close:289.000

Loading ...

Overview Company News Filings

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s (HKG:6990) 27% Price Boost Is Out Of Tune With Revenues

Simply Wall St.

Analysts Are Upgrading Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

Simply Wall St.

Announcement of Annual Results for 2024

THOMSON REUTERS

Press Release: ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024

Kelun-Biotech's Radionuclide-Drug Conjugate (Rdc) Skb107 Receives Nmpa Approval for the Treatment of Bone Metastases in Solid Tumors

THOMSON REUTERS

Analysts Just Shipped A Notable Upgrade To Their Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Estimates

Simply Wall St.

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Investigational New Drug Approval By NMPA

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Investigational New Drug Approval for Radionuclide-Drug Conjugate (Rdc) Skb107 by Nmpa

THOMSON REUTERS

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Posts FY Loss Attributable RMB266.8 Million

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - FY Loss Attributable RMB266.8 Mln

THOMSON REUTERS

Sichuan Kelun-Biotech Biopharmaceutical - FY Revenue RMB1.93 Bln

THOMSON REUTERS

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured Deposits

Sichuan Kelun-Biotech Biopharmaceutical - Co to Subscribe for 2 Structured Deposits From Bocd Each in Principal Amount of RMB50 Mln

THOMSON REUTERS

SKB Biopharma Gets Marketing Go-Ahead for Second Indication of Cancer Drug

MT Newswires Live

BRIEF-Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLC

Kelun-Biotech's Trop2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing in Second Indication by Nmpa for Egfrm Nsclc

THOMSON REUTERS

Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by Nmpa

THOMSON REUTERS

HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody

MT Newswires Live

Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy

MT Newswires Live

SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06990/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":285.4,"timestamp":1744877289037,"preClose":289,"halted":0,"volume":811904,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2796556756154556,"marketStatus":"Market Closed","change":-3.6,"latestTime":"04-17 16:08:09","open":285,"high":294,"low":275,"amount":232778521,"amplitude":0.065744,"askPrice":286.4,"askSize":300,"bidPrice":285.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.2796556756154556,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":289,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":1.0355934219983844,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.279656,"volumeRatio":1.0355934219983844,"shares":227000000,"dividePrice":0,"high":294,"amplitude":0.065744,"preClose":289,"low":275,"week52Low":120.2,"pbRate":"18.42","psRate":"31.52","week52High":346,"institutionHeld":0,"latestPrice":285.4,"eps":-1.2796556756154556,"divideRate":0,"volume":811904,"delay":0,"ttmEps":-1.2796556756154556,"open":285,"prevYearClose":163.3,"prevWeekClose":302,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":280.8,"twentyDayClose":259.4,"sixtyDayClose":162.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527795945","title":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s (HKG:6990) 27% Price Boost Is Out Of Tune With Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2527795945","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527795945?lang=en_us&edition=fundamental","pubTime":"2025-04-13 10:27","pubTimestamp":1744511222,"startTime":"0","endTime":"0","summary":"Despite an already strong run, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ( HKG:6990 ) shares have been powering...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-co-ltds-hkg6990-27-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2522167925","title":"Analysts Are Upgrading Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522167925","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522167925?lang=en_us&edition=fundamental","pubTime":"2025-03-28 09:19","pubTimestamp":1743124747,"startTime":"0","endTime":"0","summary":"It's been a good week for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ( HKG:6990 ) shareholders, because the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/analysts-are-upgrading-sichuan-kelun-biotech-biopharmaceutic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2522217258","title":"Announcement of Annual Results for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2522217258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522217258?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:29","pubTimestamp":1742984970,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA1XB61K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2522217408","title":"Press Release: ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2522217408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522217408?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:29","pubTimestamp":1742984940,"startTime":"0","endTime":"0","summary":"FINANCIAL HIGHLIGHTS -- Revenue was approximately RMB1,933.0 million,representing a year-on-year increase of 25.5%. -- Gross profit was. approximately RMB1,273.7 million, representing a year-on-year increase of. was approximately RMB266.8 million. -- Adjusted loss for the year([1]) was. approximately RMB118.5 million. -- Cash and financial assets([2]) was. approximately RMB3,075.7 million, representing a year-on-year increase of. ([2]) Comprises cash and cash equivalents, restricted deposits, financial. assets measured at fair value through profit or loss, and financial assets. CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Pharmaceutical Co., Ltd.  announced its audited consolidated results for the year ended December 31, 2024 .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","FOR","LU0196878994.USD","BK1161","BK4232","R","BK4024","BK4022"],"gpt_icon":0},{"id":"2522347857","title":"Kelun-Biotech's Radionuclide-Drug Conjugate (Rdc) Skb107 Receives Nmpa Approval for the Treatment of Bone Metastases in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522347857","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522347857?lang=en_us&edition=fundamental","pubTime":"2025-03-26 09:55","pubTimestamp":1742954123,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA6WRVRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2522862413","title":"Analysts Just Shipped A Notable Upgrade To Their Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522862413","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522862413?lang=en_us&edition=fundamental","pubTime":"2025-03-26 08:12","pubTimestamp":1742947952,"startTime":"0","endTime":"0","summary":"Celebrations may be in order for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ( HKG:6990 ) shareholders, with the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/analysts-just-shipped-a-notable-upgrade-to-their-sichuan-kel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2522005469","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Investigational New Drug Approval By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2522005469","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522005469?lang=en_us&edition=fundamental","pubTime":"2025-03-25 22:56","pubTimestamp":1742914564,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Gets Investigational New Drug Approval By NMPAMarch 25 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:INVESTIGATIONAL NEW DRUG APPROVA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q71RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2522293330","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Investigational New Drug Approval for Radionuclide-Drug Conjugate (Rdc) Skb107 by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2522293330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522293330?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:32","pubTimestamp":1742902362,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q71RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2521445837","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Posts FY Loss Attributable RMB266.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521445837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521445837?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:35","pubTimestamp":1742816150,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Posts FY Loss Attributable RMB266.8 MillionMarch 24 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:FY LOSS ATTRIBUTABLE RMB266.8 MILLIONFY REVENUE RMB1.93 BILLIONFurther company coverage: 6990.HK ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q7164:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2521805744","title":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - FY Loss Attributable RMB266.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2521805744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521805744?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:33","pubTimestamp":1742816034,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q7164:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2521744802","title":"Sichuan Kelun-Biotech Biopharmaceutical - FY Revenue RMB1.93 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2521744802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521744802?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:33","pubTimestamp":1742816034,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q7164:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2520652054","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured Deposits","url":"https://stock-news.laohu8.com/highlight/detail?id=2520652054","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520652054?lang=en_us&edition=fundamental","pubTime":"2025-03-20 23:27","pubTimestamp":1742484427,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured DepositsMarch 20  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:CO TO SUBSCRIBE FOR 2 STRUCTURED DEPOSITS FROM BOCD EACH IN PRINCIPAL AMOUNT OF RMB50 MILLIONCO TO SUBSCRIBE FOR STRUCTURED DEPOSIT FROM BOCD IN PRINCIPAL AMOUNT OF RMB100 MILLIONFurther company coverage: 6990.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2520468387","title":"Sichuan Kelun-Biotech Biopharmaceutical  - Co to Subscribe for 2 Structured Deposits From Bocd Each in Principal Amount of RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2520468387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520468387?lang=en_us&edition=fundamental","pubTime":"2025-03-20 22:36","pubTimestamp":1742481394,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2518768707","title":"SKB Biopharma Gets Marketing Go-Ahead for Second Indication of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2518768707","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518768707?lang=en_us&edition=fundamental","pubTime":"2025-03-11 14:07","pubTimestamp":1741673273,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical's  sacituzumab tirumotecan has received marketing approval from China's National Medical Products Administration for a second indication, a Monday filing with the Hong Kong bourse said.The second indication is for the treatment of adult patients with non-small cell lung cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2518760249","title":"BRIEF-Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2518760249","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518760249?lang=en_us&edition=fundamental","pubTime":"2025-03-10 18:45","pubTimestamp":1741603557,"startTime":"0","endTime":"0","summary":"BRIEF-Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved For Marketing In Second Indication By NMPA For EGFRm NSCLCMarch 10 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PS05H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2518234249","title":"Kelun-Biotech's Trop2 ADC Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing in Second Indication by Nmpa for Egfrm Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2518234249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518234249?lang=en_us&edition=fundamental","pubTime":"2025-03-10 18:44","pubTimestamp":1741603463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PS05H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2518821317","title":"Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2518821317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518821317?lang=en_us&edition=fundamental","pubTime":"2025-03-10 16:45","pubTimestamp":1741596318,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PR0D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2517185660","title":"HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185660?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:40","pubTimestamp":1741243252,"startTime":"0","endTime":"0","summary":"HBM Holdings  received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.The company and Sichuan Kelun-Biotech Biopharmaceutical  had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02142","06990","BK1574","BK1583","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2512600139","title":"Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2512600139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512600139?lang=en_us&edition=fundamental","pubTime":"2025-02-18 17:00","pubTimestamp":1739869228,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has an average rating of buy and price targets ranging from HK$187.10 to HK$240, according to analysts polled by Capital IQ.(MT Newswires covers equi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","NMR"],"gpt_icon":0},{"id":"2510805909","title":"SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2510805909","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510805909?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:00","pubTimestamp":1739268009,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  will present the results of its phase 1/2 study of its sacituzumab tirumotecan drug during a meeting of the American Society of Clinical Oncology in San Francisco from Thursday to Saturday.The drug is indicated for patients with locally advanced or metastatic urothelial carcinoma who have shown progress on or after prior anti-cancer treatments, according to a Tuesday filing with the Hong Kong exchange.The drug has previous indications for advanced solid tumors such as non-small cell lung cancer, breast cancer, gastric cancer, and gynecological tumors, among others, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post Market","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744646400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745068511327}}}